Drug Profile
CIBG 166a
Alternative Names: CIGB-166aLatest Information Update: 28 Jan 2020
Price :
$50
*
At a glance
- Originator Center for Genetic Engineering and Biotechnology
- Class Recombinant proteins
- Mechanism of Action Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer; Wet age-related macular degeneration
Most Recent Events
- 28 Jan 2020 No recent reports of development identified for research development in Cancer in Cuba
- 28 Jan 2020 No recent reports of development identified for research development in Wet age-related macular degeneration in Cuba
- 31 Dec 2015 CIBG 166a is available for licensing as of 31 Dec 2015. http://gndp.cigb.edu.cu